This activity is expired and is no longer available for CME credit.


A Vision for the Future: Reducing the Burden of Anti-VEGF Therapy With Emerging Options

Author(s)/Faculty: Nancy M. Holekamp, MD; Margaret A. Chang, MD, MS
Release Date: 10/30/2020Expiration Date: 10/29/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: LectureProvider:
Evolving advances for the treatment of neovascular retinal diseases have the potential to further enhance visual acuity outcomes while reducing treatment burden. Several novel delivery systems, along with therapies that target alternate pathways, are currently being evaluated in clinical studies. Understanding these therapeutic advances prior to their possible approval is imperative for their optimal integration into clinical practice. In this educational activity, experts in the field review the burden associated with current treatment strategies in neovascular retinal diseases, investigate the role of subretinal fluid in determining response to treatment, as well as evaluate new and emerging modalities that may reduce the burden of anti-vascular endothelial growth factor (VEGF) therapy in neovascular retinal diseases.